Please use this identifier to cite or link to this item:
Title: ReoPro Observational Registry (RAPOR): Insights from the multicentre use of abciximab in Asia
Authors: Poh, K.K. 
Tan, H.C. 
Yip, J.W.L.
Lim, Y.T. 
Keywords: Abciximab
Adjuvant drug therapy
Coronary disease
Percutaneous coronary intervention
Issue Date: Aug-2005
Citation: Poh, K.K., Tan, H.C., Yip, J.W.L., Lim, Y.T. (2005-08). ReoPro Observational Registry (RAPOR): Insights from the multicentre use of abciximab in Asia. Singapore Medical Journal 46 (8) : 407-413. ScholarBank@NUS Repository.
Abstract: Introduction: The pattern of use of abciximab in real-life clinical patients undergoing percutaneous coronary intervention (PCI) in 11 high-volume centres in Singapore, Malaysia, Thailand, Philippines, India, Pakistan and Korea was prospectively examined. Methods: These centres enrolled 224 consecutive patients over eight months to receive abciximab during PCI for the study. The cohort consisted of 82.1 percent males, with mean age of 55 (±11) years and mean weight of 67 (±17) kg. Results: The use of abciximab during PCI ranged between 6.2 percent and 21.6 percent. The indications for the use of abciximab were: acute coronary syndromes (34.3 percent), complex coronary lesions (17.9 percent) and multivessel PCI (17.7 percent). Based on a risk scoring system devised for this registry, majority (60.0 percent) of the patients was considered high risk when abciximab was used. Among the patients enrolled, 36.6 percent received abciximab as a "bail-out". The overall in-hospital ischaemic event rates were low at 4.0 percent. The complication rates included major bleeding 0.7 percent, thrombocytopenia 2.7 percent and need for blood transfusion 2.8 percent. There was a trend towards a higher incidence of in-hospital non-Q myocardial infarction in the "bail-out" group (2.1 percent versus 7.3 percent, p-value equals 0.07). Conclusion: Abxicimab was uncommonly used among patients (9.4 percent) undergoing PCI in this Asian region, with the operators reserving it mainly for high-risk patients.
Source Title: Singapore Medical Journal
ISSN: 00375675
Appears in Collections:Staff Publications

Show full item record
Files in This Item:
There are no files associated with this item.

Page view(s)

checked on Jun 6, 2019

Google ScholarTM


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.